
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is well-positioned for growth with a diverse product portfolio and a strong presence in international markets. Positive catalysts, such as upcoming key trials and a potential new standard of care in prostate cancer, could drive sales and expand market share. However, sustainability issues, such as inconsistent integration and potential negative impacts from cost-cutting measures, could hinder long-term growth and credibility. Risks to the rating and price target include challenges to key patents and negative pipeline trial results. Additionally, diversity at the C-suite level remains a concern, though recent initiatives may improve representation.
Bears say
Pfizer is facing significant challenges in terms of its growth potential due to upcoming patent expirations and a slow pipeline of new drugs in development. The company's recent M&A deals have been mixed and there are concerns about its ability to maintain its dividend payout ratio and fund future M&A opportunities. In addition, the company's obesity candidate drugs appear to be lagging behind competitors and it has faced recent setbacks in patent disputes, adding to the risk surrounding the stock.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares